Extract
Since 2016, chronic obstructive pulmonary disease (COPD) has been the third-leading cause of death worldwide, with an estimated 3 million deaths (5.3% of all deaths), but with large regional variations (www.who.int/healthinfo/global_burden_disease/projections/en/). Observed data from high-income countries [1–4] (HICs) and modelled data in two global studies [5, 6] have reported declines in COPD mortality rates since the 1990s. Globally, since 2006, modelled COPD mortality rates decreased by 21% [7]. Yet, little is known about observed trends in COPD mortality in Latin America, and more recently in Oceania and Europe.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Lortet-Tieulent has nothing to disclose.
Conflict of interest: Dr. Soerjomataram has nothing to disclose.
Conflict of interest: Dr. Lopez-Campos reports personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants, personal fees and non-financial support from Chiesi, personal fees and non-financial support from CSL Behring, grants, personal fees and non-financial support from Esteve, personal fees and non-financial support from Ferrer, grants, personal fees and non-financial support from GebroPharma, grants, personal fees and non-financial support from GlaxoSmithKline, grants, personal fees and non-financial support from Grifols, grants, personal fees and non-financial support from Menarini, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Rovi, grants, personal fees and non-financial support from Teva, outside the submitted work.
Conflict of interest: Dr. Ancochea has nothing to disclose.
Conflict of interest: Dr. Coebergh has nothing to disclose.
Conflict of interest: JBS participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer-Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. JBS declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
